Index RUT
P/E -
EPS (ttm) -4.56
Insider Own 1.41%
Shs Outstand 75.37M
Perf Week 19.01%
Market Cap 476.39M
Forward P/E -
EPS next Y -1.85
Insider Trans -5.26%
Shs Float 75.03M
Perf Month -9.93%
Income -337.40M
PEG -
EPS next Q -0.94
Inst Own 116.02%
Short Float 15.73%
Perf Quarter -26.27%
Sales 198.84M
P/S 2.40
EPS this Y -94.39%
Inst Trans 0.10%
Short Ratio 9.60
Perf Half Y -6.85%
Book/sh 2.66
P/B 2.35
EPS next Y 36.70%
ROA -47.87%
Short Interest 11.80M
Perf Year -60.65%
Cash/sh 7.45
P/C 0.84
EPS next 5Y -
ROE -287.12%
52W Range 5.12 - 19.54
Perf YTD -30.37%
Dividend Est. -
P/FCF -
EPS past 5Y -12.34%
ROI -56.17%
52W High -67.97%
Beta 0.70
Dividend TTM -
Quick Ratio 3.41
Sales past 5Y 3.07%
Gross Margin 69.95%
52W Low 22.27%
ATR (14) 0.40
Dividend Ex-Date -
Current Ratio 3.47
EPS Y/Y TTM -4.33%
Oper. Margin -171.72%
RSI (14) 48.85
Volatility 7.72% 6.22%
Employees 380
Debt/Eq 2.02
Sales Y/Y TTM -6.21%
Profit Margin -169.68%
Recom 1.69
Target Price 15.00
Option/Short Yes / Yes
LT Debt/Eq 1.99
EPS Q/Q -15.12%
Payout -
Rel Volume 0.62
Prev Close 6.16
Sales Surprise 8.08%
EPS Surprise -1.94%
Sales Q/Q -19.35%
Earnings May 06 AMC
Avg Volume 1.23M
Price 6.26
SMA20 3.12%
SMA50 -11.88%
SMA200 -32.05%
Trades
Volume 767,564
Change 1.62%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-27-24 Downgrade
Guggenheim
Buy → Neutral
Dec-05-23 Upgrade
Citigroup
Neutral → Buy
$7 → $10
Nov-20-23 Initiated
Citigroup
Neutral
$7
Sep-22-23 Downgrade
Wells Fargo
Overweight → Equal Weight
$24 → $8
Sep-21-23 Downgrade
William Blair
Outperform → Mkt Perform
Sep-06-23 Resumed
Evercore ISI
Outperform
$30
Jul-21-23 Initiated
JP Morgan
Overweight
$26
Jun-07-23 Resumed
Piper Sandler
Neutral
$22
May-22-23 Initiated
TD Cowen
Outperform
$30
May-05-23 Upgrade
Bryan Garnier
Sell → Neutral
Mar-01-23 Initiated
Guggenheim
Buy
$37
Feb-21-23 Upgrade
Wedbush
Neutral → Outperform
$30
Dec-14-22 Initiated
Stifel
Hold
$22
Dec-05-22 Initiated
Wells Fargo
Overweight
$28
Sep-21-22 Initiated
Bryan Garnier
Sell
$17
Jul-14-22 Resumed
Canaccord Genuity
Buy
$49 → $42
Mar-31-22 Initiated
Piper Sandler
Overweight
$42
Feb-28-22 Initiated
H.C. Wainwright
Buy
$45
May-26-21 Downgrade
Wedbush
Outperform → Neutral
$19
Show Previous Ratings
Apr-29-24 04:30PM
Apr-24-24 07:05AM
03:00AM
Apr-04-24 04:30PM
Apr-03-24 04:30PM
05:00PM
Loading…
Mar-13-24 05:00PM
Mar-11-24 07:05AM
Feb-26-24 04:30PM
Feb-23-24 07:05AM
02:00AM
Feb-16-24 09:52AM
Feb-15-24 04:01PM
Feb-08-24 04:30PM
Feb-01-24 04:30PM
Jan-25-24 04:05PM
07:00AM
Loading…
Jan-08-24 07:00AM
Jan-02-24 04:30PM
Dec-14-23 07:30AM
Dec-04-23 04:05PM
Nov-21-23 04:30PM
Nov-09-23 06:26PM
Nov-07-23 04:01PM
Nov-03-23 10:46AM
Oct-24-23 04:30PM
Oct-13-23 04:30PM
Oct-11-23 05:00PM
Sep-26-23 04:30PM
Sep-22-23 09:38AM
Sep-21-23 07:30AM
Sep-11-23 05:00PM
08:30AM
Loading…
Sep-05-23 08:30AM
08:30AM
Aug-31-23 04:30PM
Aug-24-23 04:30PM
Aug-14-23 05:00PM
Aug-08-23 06:03AM
Aug-03-23 04:01PM
Jul-26-23 12:28PM
Jul-20-23 04:30PM
Jul-17-23 08:00AM
08:00AM
Jul-11-23 05:00PM
Jun-14-23 05:00PM
Jun-08-23 04:30PM
Jun-01-23 04:30PM
May-31-23 07:00AM
May-11-23 05:00PM
May-04-23 04:01PM
May-01-23 04:05PM
Apr-26-23 04:30PM
Apr-13-23 05:00PM
Apr-01-23 04:30AM
Mar-28-23 04:30PM
Mar-23-23 04:30PM
Mar-14-23 05:00PM
04:30PM
Mar-03-23 04:05PM
Feb-28-23 10:36PM
Feb-27-23 04:01PM
Feb-25-23 07:35AM
Feb-23-23 04:01PM
Feb-17-23 06:30PM
04:04PM
04:04PM
Feb-16-23 04:30PM
Feb-13-23 05:00PM
Feb-08-23 04:30PM
Jan-12-23 07:00PM
Jan-09-23 07:00AM
Jan-03-23 04:30PM
Dec-14-22 05:00PM
Nov-16-22 05:00PM
Nov-15-22 08:00AM
Nov-09-22 04:30PM
Oct-27-22 04:01PM
Oct-26-22 04:30PM
Oct-20-22 04:30PM
Oct-13-22 04:05PM
Oct-11-22 05:00PM
Sep-14-22 05:00PM
Aug-25-22 04:30PM
Aug-22-22 07:00AM
Aug-11-22 05:00PM
Aug-04-22 07:00AM
Aug-03-22 04:05PM
Jul-28-22 04:30PM
Jul-12-22 05:00PM
Jun-20-22 09:18AM
Jun-14-22 05:00PM
Jun-02-22 04:30PM
May-17-22 04:30PM
May-16-22 04:09PM
(Investor's Business Daily) +6.13%
07:00AM
May-11-22 05:00PM
May-05-22 04:01PM
May-03-22 04:30PM
Apr-28-22 04:30PM
Apr-20-22 04:30PM
Apr-12-22 05:00PM
Apr-11-22 08:08AM
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Cline Christopher R. CHIEF FINANCIAL OFFICER Apr 11 '24 Sale 6.74 54 364 70,849 Apr 12 04:05 PM Dube Eric M CHIEF EXECUTIVE OFFICER Feb 01 '24 Sale 8.70 19,122 166,435 350,600 Feb 02 04:06 PM REED ELIZABETH E SVP, GC & CORPORATE SECRETARY Feb 01 '24 Sale 8.71 4,764 41,495 76,270 Feb 02 04:05 PM ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D Feb 01 '24 Sale 8.71 4,764 41,495 80,720 Feb 02 04:05 PM Heerma Peter CHIEF COMMERCIAL OFFICER Feb 01 '24 Sale 8.53 4,195 35,789 99,503 Feb 02 04:05 PM Cline Christopher R. CHIEF FINANCIAL OFFICER Feb 01 '24 Sale 8.53 3,818 32,573 70,903 Feb 02 04:05 PM Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER Feb 01 '24 Sale 8.53 2,820 24,058 52,017 Feb 02 04:05 PM Inrig Jula CHIEF MEDICAL OFFICER Feb 01 '24 Sale 8.53 2,174 18,547 58,074 Feb 02 04:05 PM Dube Eric M CHIEF EXECUTIVE OFFICER Jan 23 '24 Sale 8.96 7,873 70,542 234,722 Jan 25 04:10 PM ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D Jan 23 '24 Sale 8.96 2,062 18,476 60,484 Jan 25 04:10 PM REED ELIZABETH E SVP, GC & CORPORATE SECRETARY Jan 23 '24 Sale 8.96 2,062 18,476 56,034 Jan 25 04:10 PM Heerma Peter CHIEF COMMERCIAL OFFICER Jan 23 '24 Sale 9.07 1,559 14,138 78,698 Jan 25 04:10 PM Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER Jan 23 '24 Sale 9.07 910 8,252 41,337 Jan 25 04:10 PM Cline Christopher R. CHIEF FINANCIAL OFFICER Jan 23 '24 Sale 9.07 853 7,735 49,721 Jan 25 04:10 PM Inrig Jula Chief Medical Officer Jan 04 '24 Sale 9.17 440 4,035 35,248 Jan 05 04:11 PM Inrig Jula Chief Medical Officer Jan 03 '24 Sale 9.48 2,069 19,613 35,688 Jan 05 04:11 PM Heerma Peter Chief Commercial Officer Oct 03 '23 Sale 8.25 3,091 25,504 80,257 Oct 04 04:05 PM Dube Eric M Chief Executive Officer Sep 05 '23 Sale 14.71 4,455 65,533 242,595 Sep 05 08:10 PM ROTE WILLIAM E. Senior Vice President, R&D Sep 05 '23 Sale 14.71 1,815 26,699 61,173 Sep 05 08:13 PM REED ELIZABETH E SVP, GC & Corporate Secretary Sep 05 '23 Sale 14.71 1,815 26,699 58,096 Sep 05 08:12 PM Cline Christopher R. Chief Financial Officer Sep 05 '23 Sale 14.71 457 6,723 50,574 Sep 05 08:15 PM Calvin Sandra SVP, Chief Accounting Officer May 11 '23 Sale 16.12 122 1,967 42,247 May 12 04:06 PM REED ELIZABETH E SVP, GC & Corporate Secretary May 10 '23 Sale 16.59 825 13,687 56,611 May 12 04:11 PM ROTE WILLIAM E. Senior Vice President, R&D May 10 '23 Sale 16.59 825 13,687 59,211 May 12 04:09 PM Cline Christopher R. Chief Financial Officer May 10 '23 Sale 16.59 455 7,548 51,031 May 12 04:14 PM Calvin Sandra SVP, Chief Accounting Officer May 10 '23 Sale 16.59 436 7,233 42,369 May 12 04:06 PM
Index -
P/E -
EPS (ttm) -1.84
Insider Own 30.87%
Shs Outstand 8.40M
Perf Week -4.27%
Market Cap 17.25M
Forward P/E -
EPS next Y -1.42
Insider Trans 0.00%
Shs Float 5.90M
Perf Month -10.22%
Income -15.42M
PEG -
EPS next Q -0.57
Inst Own 7.05%
Short Float 1.46%
Perf Quarter 18.82%
Sales 0.00M
P/S -
EPS this Y -6.83%
Inst Trans 12.62%
Short Ratio 0.97
Perf Half Y -19.20%
Book/sh 1.44
P/B 1.41
EPS next Y 27.37%
ROA -71.76%
Short Interest 0.09M
Perf Year -22.61%
Cash/sh 1.56
P/C 1.29
EPS next 5Y -
ROE -84.04%
52W Range 1.56 - 4.08
Perf YTD 14.77%
Dividend Est. -
P/FCF -
EPS past 5Y 56.03%
ROI -126.94%
52W High -50.49%
Beta 1.46
Dividend TTM -
Quick Ratio 5.05
Sales past 5Y 0.00%
Gross Margin -
52W Low 29.49%
ATR (14) 0.22
Dividend Ex-Date -
Current Ratio 5.05
EPS Y/Y TTM -5.91%
Oper. Margin 0.00%
RSI (14) 39.86
Volatility 8.72% 9.31%
Employees 7
Debt/Eq 0.01
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 10.00
Option/Short No / Yes
LT Debt/Eq 0.01
EPS Q/Q -7.83%
Payout -
Rel Volume 0.03
Prev Close 2.01
Sales Surprise -
EPS Surprise 14.81%
Sales Q/Q -
Earnings Mar 13 BMO
Avg Volume 88.89K
Price 2.02
SMA20 -16.12%
SMA50 -10.20%
SMA200 -9.33%
Trades
Volume 2,890
Change 0.75%
Apr-11-24 07:30AM
Mar-28-24 08:00AM
Mar-25-24 08:30AM
Mar-18-24 08:00AM
Mar-13-24 07:30AM
07:30AM
Loading…
Mar-04-24 07:30AM
Feb-15-24 08:00AM
Feb-08-24 08:00AM
Jan-04-24 08:00AM
Nov-06-23 04:01PM
08:00AM
Oct-31-23 09:01AM
Sep-27-23 08:00AM
Sep-26-23 08:00AM
Sep-19-23 08:00AM
08:05AM
Loading…
Sep-06-23 08:05AM
Aug-14-23 08:00AM
Aug-10-23 08:45AM
Aug-07-23 08:00AM
Jun-15-23 08:00AM
May-31-23 08:30AM
May-11-23 07:00AM
May-09-23 08:00AM
May-01-23 08:00AM
Apr-24-23 09:00AM
Apr-20-23 04:05PM
Apr-19-23 09:28AM
08:05AM
Apr-17-23 08:00AM
Mar-22-23 08:00AM
08:00AM
Loading…
Mar-17-23 08:00AM
Mar-15-23 08:05AM
Mar-13-23 08:05AM
Mar-07-23 08:05AM
Feb-14-23 08:00AM
Feb-07-23 08:05AM
Dec-13-22 07:30AM
Nov-10-22 04:05PM
Oct-18-22 07:00AM
Sep-06-22 09:02AM
Aug-08-22 08:00AM
Jun-09-22 07:00AM
Jun-03-22 07:00AM
May-23-22 08:00AM
May-19-22 07:00AM
May-18-22 04:15PM
May-12-22 08:00AM
May-03-22 12:20PM
Apr-20-22 07:00AM
Mar-23-22 07:00AM
Mar-21-22 07:00AM
Mar-17-22 07:00AM
Mar-07-22 07:00AM
Jan-14-22 09:38AM
Jan-05-22 07:00AM
Jan-03-22 07:00AM
Dec-01-21 08:00AM
Nov-15-21 07:00AM
Nov-04-21 10:51AM
Sep-15-21 07:00AM
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Anderson Glen R. 10% Owner Aug 14 '23 Buy 2.34 23,934 56,006 1,190,400 Aug 16 06:01 PM Anderson Glen R. 10% Owner Aug 11 '23 Buy 2.12 35,064 74,336 1,166,466 Aug 16 06:01 PM Anderson Glen R. 10% Owner Aug 10 '23 Buy 1.94 44,354 86,047 1,131,402 Aug 16 06:01 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite